Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TauRx Completes $135 Million Financing for Alzheimer Drug

publication date: Oct 9, 2015
TauRx Pharmaceuticals, a Singapore biopharmaceutical company, completed a $135 million equity financing through a combination of new investors and existing shareholders. The funds will support development of its lead compound, LMTX® that is currently in Phase III clinical trials for Alzheimer's disease and Frontotemporal Dementia (FTD) in over 20 countries and 17,000 subjects. TauRx's website lists Temasek (Singapore’s sovereign wealth investment organization), the Development Bank of Singapore, the Dundee Corporation of Canada, as well as the Genting group of companies as investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital